Wil je inschrijven op overheidsaanbestedingen? Bekijk onze TaaS aanbestedingsvoorbereidingsservice
Aanbestedingen

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

Gesloten

Deadline voor indiening verstreken

De deadline voor het indienen van deze aanbesteding is verstreken en er worden geen aanvragen meer geaccepteerd. De onderstaande informatie wordt ter referentie bewaard.

Bekijk actieve aanbestedingen
Deadline
Verlopen
9 maart 2026
Contractdetails
Categorie
Open Procedure
Referentie
010573-2026
Waarde
£40,778,314
Locatie
North East England, Verenigd Koninkrijk
Gepubliceerd
24 juli 2026
Organisatie
CPV-code
Projecttijdlijn

Aanbesteding gepubliceerd

5 februari 2026

Deadline voor vragen

2 maart 2026

Deadline voor inschrijving

9 maart 2026

Startdatum contract

31 mei 2026

Buyer IntelligencePRO
🔒
Ontgrendel Buyer Intelligence
Bekijk uitgavenpatronen, voorkeursprocedures en meer.
Upgrade naar Professional →
Budget
£40,778,314
Looptijd
24 maanden
Locatie
North East England
Type
Open Procedure
52
Kwaliteitsscore/100
Redelijk

Originele aanbestedingsbeschrijving

NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. Offer reference number: CM/PHG/24/5716. Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Periods of call-offs under the framework agreement: CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Risicoanalyse

Risicoanalyse is nog niet beschikbaar voor aanbestedingen uit dit land. Momenteel ondersteund: Estland, Letland, Litouwen, Polen, Frankrijk, VK, Denemarken, Nederland, Noorwegen en Finland.

Winststrategie

Ontvang een AI-gestuurde winnende strategie, afgestemd op deze aanbesteding. Inclusief winstkansscore, belangrijke kansen en uitdagingen, aanbevolen focusgebieden voor de inschrijving, inzichten in concurrentiepositie en actiegerichte aanbevelingen om je kansen te maximaliseren.

Inloggen

Concurrenten

Upgrade om te zien welke bedrijven waarschijnlijk op deze aanbesteding zullen inschrijven, gebaseerd op historische inkoopgegevens.

Inloggen

Vereisten & Kwalificaties

7 vereisten over 5 categorieën

Indiening (1)
Verplicht (1)
Naleving (3)
Technisch (1)
Financieel (1)
SUBMISSION REQUIREMENTS1
--Submit the bid by the deadline: 2026-03-09 at 13:00:00 UTC.
MANDATORY EXCLUSION GROUNDS1
--No specific mandatory exclusion grounds are detailed in the provided information.
ELIGIBILITY REQUIREMENTS3
--Be capable of supplying Lenalidomide, Pomalidomide, and Thalidomide.
--Be able to operate within a national framework agreement for NHS England.
--Be able to deliver pharmaceutical products to specified UK regions (Midlands, Southwest, Northwest, London North, London South, Northeast).
TECHNICAL CAPABILITY REQUIREMENTS1
--No specific technical capability requirements are detailed in the provided information.
FINANCIAL REQUIREMENTS1
--No specific financial requirements are detailed in the provided information.

Voorbeeld van vereisten

Meld je aan om volledige vereisten en analyse te bekijken

Documenten

3 documenten beschikbaar met AI-samenvattingen

OCDS RecordDOC
010573-2026_ocds_record.json

This OCDS record provides structured data about NHS England's national framework for Lenalidomide, Pomalidomide & Thalidomide, detailing its planning phase and linking to the official procurement notice.

OCDS Release PackageDOC
010573-2026_ocds_release.json

This OCDS data package provides structured information about NHS England's national framework tender for Lenalidomide, Pomalidomide, and Thalidomide, covering various UK regions from June 2026 for up to 48 months.

Official PDF VersionPDF
010573-2026_official.pdf

This document is a published tender notice from NHS England for a national framework agreement covering Lenalidomide, Pomalidomide, and Thalidomide, detailing the framework period from June 2026 to May 2028 with potential extensions, an estimated value of £33.9 million, and contract locations across the UK.

Voorbeeld van documenten

Meld je aan om document samenvattingen en analyse te bekijken

52
Redelijk

Kwaliteitsscore aanbesteding

This tender exhibits significant deficiencies in documentation accessibility, clarity of requirements, and transparency of evaluation criteria, posing substantial risks to a fair and effective procurement process.

Scoreoverzicht

Wettelijke naleving65/100

Despite clear basic deadlines and procedure type, the inaccessibility of critical tender documents and the absence of detailed mandatory exclusion grounds, technical/financial requirements, and evaluation criteria represent serious breaches of legal compliance principles.

Inaccessible critical tender documents ('Page not found', 'Download failed')
Missing detailed mandatory exclusion grounds
Duidelijkheid45/100

While the general description of the framework and products is clear, the explicit lack of detailed mandatory exclusion grounds, technical, financial requirements, and especially evaluation criteria, renders the tender fundamentally unclear for potential bidders.

Missing detailed mandatory exclusion grounds
Missing detailed technical capability requirements
Volledigheid45/100

Basic information such as title, organization, value, and duration is present. However, the inaccessibility of key tender documents and the explicit absence of detailed requirements (exclusion, technical, financial) and evaluation criteria make the tender significantly incomplete.

Inaccessible critical tender documents ('Page not found', 'Download failed')
Missing detailed mandatory exclusion grounds
Eerlijkheid35/100

The inaccessibility of critical tender documents and the complete absence of specified evaluation criteria are severe fairness issues. The lack of electronic submission also presents a barrier to equal access for all potential bidders.

Inaccessible critical tender documents
Missing evaluation criteria
Praktische uitvoerbaarheid55/100

The absence of electronic submission capabilities is a significant practical drawback in modern procurement. Furthermore, the inaccessible tender documents make it impractical for bidders to gather necessary information and prepare a comprehensive offer.

No electronic submission supported
Inaccessible critical tender documents
Gegevensconsistentie85/100

Key data fields such as title, reference, organization, estimated value, and timeline are largely consistent. Minor inconsistencies include empty fields for 'Liable Person' and procedure codes.

"Liable Person" field is empty
"Type (Code)" and "Procedure (Code)" fields are empty
Duurzaamheid25/100

The tender does not include any explicit mention of green procurement, social aspects, or innovation focus, indicating a missed opportunity to integrate broader sustainability objectives.

No green procurement criteria
No social criteria

Sterke punten

Clear basic information (title, organization, value, duration)
Well-defined scope for pharmaceutical products and regions
Open procedure, promoting competition
Value disclosed, not classified
CPV code correctly assigned

Aandachtspunten

Critical tender documents are inaccessible ('Page not found', 'Download failed')
Absence of detailed mandatory exclusion grounds, technical, and financial requirements
Crucially, no evaluation criteria are specified
No electronic submission supported
Lack of any sustainability, social, or innovation considerations

Aanbevelingen

1. Immediately rectify the issues with inaccessible tender documents to ensure full transparency and legal compliance.
2. Publish comprehensive and detailed mandatory exclusion grounds, eligibility, technical, and financial requirements.
3. Clearly define and publish objective evaluation criteria to ensure fairness and transparency for all bidders.

Voorbeeld van AI-score

Meld je aan om volledige vereisten en analyse te bekijken

Volledige analyse van de kwaliteitsscore
Gedetailleerde uitsplitsing van subscores
Inzichten in sterke en zwakke punten
Strategische aanbevelingen

Geen creditcard vereist • Setup in 2 minuten

Toevoegen aan pipeline